阿尔茨海默病患者与健康人群的血铅水平比较。
Comparison of Blood Lead Levels in Patients With Alzheimer's Disease and Healthy People.
机构信息
1 Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Birjand, Iran.
2 Department of Neurology, Birjand University of Medical Sciences, Complementary Alternative Medicine Research Center, Valiasr Hospital, Birjand, Iran.
出版信息
Am J Alzheimers Dis Other Demen. 2018 Dec;33(8):541-547. doi: 10.1177/1533317518794032. Epub 2018 Aug 22.
BACKGROUND
It is argued that breakdown of β-amyloid in the brain causes deposition of senescent plaques and therefore Alzheimer's disease (AD). One of the influential factors for increasing level of this protein is exposure to lead. Our aim was to compare blood lead levels (BLLs) between patients with AD and healthy controls.
METHODS
This case-control study was performed on all patients with cognitive impairment who were referred to the Neurological Clinic of Birjand in 2016 to 2017. Patients were referred to the laboratory for measurement of their serum levels of lead. The controls and patients were matched by age and sex.
RESULTS
In the AD case group, the average BLL was 22.22 ± 28.57 μg/dL. Mann-Whitney U test showed that BLLs were significantly higher in the patients than in the controls. The unadjusted odds ratio for BLL among the patients was 1.05 (95% confidence interval: 1.01-1.09; P = .01) compared to the controls.
CONCLUSION
In the present study, BLL was associated with AD.
背景
据认为，大脑中β-淀粉样蛋白的破裂导致衰老斑块的沉积，从而导致阿尔茨海默病（AD）。增加这种蛋白质水平的一个影响因素是接触铅。我们的目的是比较 AD 患者和健康对照组之间的血铅水平（BLL）。
方法
本病例对照研究于 2016 年至 2017 年期间在比尔詹德神经科诊所对所有有认知障碍的患者进行。患者被转介到实验室测量其血清铅水平。对照组和患者按年龄和性别匹配。
结果
在 AD 病例组中，平均 BLL 为 22.22±28.57μg/dL。Mann-Whitney U 检验显示，患者的 BLL 明显高于对照组。与对照组相比，患者的 BLL 未调整比值比为 1.05（95%置信区间：1.01-1.09；P=0.01）。
结论
本研究表明，BLL 与 AD 相关。
Zotero 插件